Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: subsets of responses
American Journal of Medicine
A comparison of placebo, auranofin, and parenteral gold sodium thiomalate therapy in 209 patients with active rheumatoid arthritis was performed in a 21-week prospective, controlled, double-blind multicenter trial. When the 161 patients who completed at least 20 weeks of treatment were analyzed for different degrees of response, no remissions were identified. When 50 percent or greater improvement of pain/tenderness scores were compared for end of trial versus entry values, 9 percent of placebo-treated patients, 34 percent of auranofin-treated patients, and 48 percent of gold sodium thiomalate-treated patients showed important improvement that was statistically significant for both gold treatments.
Ward, J. R.,
Williams, H. J.,
Boyce, E. G.,
Egger, M. J.,
Reading, J. C.,
Samuelson, C. O.
Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: subsets of responses.
American Journal of Medicine, 75(6), 133–137.